Reduced inhibitor 1 and 2 activity is associated with increased protein phosphatase type 1 activity in left ventricular myocardium of one-kidney, one-clip hypertensive rats

Molecular and Cellular Biochemistry

Volumn 269, Issue 1, 2005, Pages 49-57

  Gupta, Ramesh H ^a   Mishra, Sudhish ^a   Yang, Xiao Ping ^a   Sabbah, Hani N ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Heart failure; Inhibitor 1; Inhibitor 2; Phospholamban; Protein phosphatases; Protein phosphorylation

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CALCIUM BINDING PROTEIN; CALSEQUESTRIN; PHOSPHOLAMBAN; PHOSPHOPROTEIN; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR 1; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR 2; PHOSPHORUS 32; PHOSPHORYLASE; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CATALYSIS; CHRONIC DISEASE; CLIP; COMPARATIVE STUDY; CONTROLLED STUDY; DENSITOMETRY; ENZYME ACTIVITY; ENZYME SUBSTRATE; ENZYME SUBUNIT; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; IMMUNOPRECIPITATION; ISOTOPE LABELING; LUNG CONGESTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RAT; RENOVASCULAR HYPERTENSION; SARCOPLASMIC RETICULUM; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; TISSUE HOMOGENATE; TISSUE LEVEL;

ANIMALS; CARDIAC OUTPUT, LOW; HEART VENTRICLES; HYPERTENSION, RENOVASCULAR; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIUM; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHORYLATION; PROTEINS; RATS;

EID: 14244249503     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11010-005-2538-x     Document Type: Article

References (41)

1. Pathophysiology of heart failure. Identifying targets for pharmacotherapy. Med Clin North Am 87: 303-316, 2003 1:CAS:528:DC%2BD3sXjtVChtL8%3D
2. Petrashevskaya NN, Koch SE, Bodi I, Schwartz A: Calcium cycling, historic overview and perspectives. Role for autonomic nervous system regulation. J Mol Cell Cardiol 34: 885-896, 2002
3. Hersiz S, Neumann J: Effects of serine/threonine protein phosphatases on ion channels in excitable membranes. Physiol Rev 80: 173-210, 2000 1:CAS:528:DC%2BD3cXmtl2jtQ%3D%3D
4. Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J, Grazette L, Michael A, Hajjar R, Force T, Molkentin JD: Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 103: 670-677, 2001 1:STN:280:DC%2BD3M3msFWluw%3D%3D
5. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93: 215-228, 1998 10.1016/S0092-8674(00)81573-1
6. Oie E, Bjornerheim R, Clausen OP, Attramadal H: Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats. Am J Physiol Heart Circ Physiol 278: H2115-H2123, 2000
7. 2+ handling in a calcineurin transgenic model of heart failure. Cardiovasc Res 54: 105-116, 2002
8. RJ Solaro 1986 Protein phosphorylation and cardiac myofilaments RJ Solaro Protein Phosphorylation in Heart Muscle CRC Press Boca Raton, FL 129-156
9. Gupta RC, Neumann J, Durant P, Watanabe AM: Comparison of adenosine and muscarinic receptor-mediated effects of protein phosphatase inhibitor activity in the heart. J Pharmacol Exp Ther 266: 16-22, 1993
10. Gupta RC, Neumann J, Watanabe AM, Lesch M, Sabbah HN: Evidence for presence and hormonal regulation of protein phosphatase inhibitor-1 in ventricular cardiomyocytes. Am J Physiol Heart Circ Physiol 270: H1159-H1164, 1996
11. Neumann J, Gupta RC, Schmitz W, Scholz H, Nairn AC, Watanabe AM: Evidence for isoproterenol-induced phosphorylation of protein phosphatase inhibitor-1 in the intact heart. Circ Res 69: 1450-1457, 1991
12. Gupta RC, Neumann J, Watanabe AM, Sabbah HN: Inhibition of type 1 protein phosphatase activity by activation of β-adrenoceptors in ventricular myocardium. Biochem Pharmacol 63: 1069-1076, 2002
13. 2+-dependent protein phosphatase by the mitogen-activated protein kinase. J Biol Chem 270: 18352-18358, 1995
14. Neumann J, Eschenhagen T, Jones LR, Linck B, Schmitz W, Scholz H, Zimmermann N: Increased expression of cardiac phosphatases in patients with end-stage heart failure. J Mol Cell Cardiol 29: 265-272, 1997
15. Huang B, Wang S, Qin D, Boutjdir M, El-Sherif N: Diminished basal phosphorylation level of phospholamban in the postinfarction remodeled rat ventricle: Role of β-adrenergic pathway, Gi protein, phosphodiesterase, and phosphatases. Circ Res 85: 848-855, 1999
16. 2+/calmodulin-dependent protein kinase is altered in heart failure. Circ Res 86: 596-605, 2000
17. 2+ uptake in human failing left ventricular myocardium. J Heart Lung Transplant 21: 366-373, 2002
18. El-Armouche A, Pamminger T, Ditz D, Zolk O, Eschenhagen T: Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing hearts. Cardiovasc Res 61: 87-93, 2004
19. Carr AN, Schmidt AG, Suzuki Y, Monte FD, Sato Y, Lanner C, Breeden K, Jing SL, Allen PB, Greengard P, Yatani A, Hoit BD, Grupp IL, Hajjar RJ, DePaoli-Roach AA, Kranias EG: Type-1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol 22: 4124-4135, 2002
20. Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, Kimball TF, Lorenz JN, Nairn AC, Liggett SB, Bodi I, Wang S, Schwartz A, Lakatta EG, De Paoli-Roach AA, Robbins J, Hewett TE, Bibb JA, Westfall MV, Kranias EG, Molkentin JD: PKC-a regulates cardiac contractility and propensity toward heart failure. Nat Med 10: 248-254, 2004
21. Gupta RC, Mishra S, Rastogi S, Imai M, Habib O, Sabbah HN: Cardiac SR-coupled PP1 activity and expression are increased and inhibitor-1 expression is decreased in failing hearts. Am J Physiol Heart Circ Physiol 285: H2373-H2381, 2003
22. 2+-uptake during the development of left ventricular hypertrophy. Biochem Pharmacol 65: 933-939, 2003
23. 2+ calmodulin-dependent protein kinase in failing and nonfailing human hearts. Cardiovasc Res 42: 254-261, 1999
24. Liu YH, Yang XP, Nass O, Sabbah HN, Peterson E, Carretereo OA: Chronic heart failure induced by coronary artery ligation in Lewis inbred rats. Am J Physiol Heart Circ Physiol 272: H722-H727, 1997
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1951
26. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976 10.1006/abio.1976.9999
27. 2+-ATPase activity and expression in ventricular myocardium of dogs with heart failure. Am J Physiol 273: H12-H18, 1997
28. 2+-uptake and expression of phospholamban in left ventricular myocardium of dogs with heart failure. J Mol Cell Cardiol 31: 1381-1389, 1999
29. Sventek P, Turgeon A, Garcia R, Schiffrin EL: Vascular and cardiac overexpression of endothelin-1 gene in one-kidney, one clip Goldblatt hypertensive rats but only in the late phase of two-kidney one clip Goldblatt hypertension. J Hypertens 14: 57-64, 1996
30. Ge C, Garcia R, Anand-Srivastava MB: Altered expression of Gi-protein and adenylyl cyclase activity in hearts from one kidney one clip hypertensive rats: Effect of captopril. J Hypertens 17: 1617-1626, 1999
31. Sabbah HN, Sharov VG, Gupta RC, Mishra S, Rastogi S, Undrovinas AI, Chaudhry PA, Todor A, Mishima T, Tanhehco EJ, Suzuki G: Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment. Circ Res 93: 1020-1022, 2003
32. Kaiser RA, Bueno OF, Lips DJ, Doevendans PA, Jones F, Kimball TF, Molkentin JD: Targeted inhibition of p38 MAPK antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J Biol Chem 279: 15524-15530, 2004
33. Everett AD, Stoops TD, Nairn AC, Brautigan D: Angiotensin II regulates phosphorylation of translation elongation factor-2 in cardiac myocytes. Am J Physiol Heart Circ Physiol 281: H161-H167, 2001
34. 2+ channel density and regulation are altered in failing human ventricular myocytes and recover after support with mechanical assist devices. Circ Res 91: 517-524, 2002
35. 2+ exchanger in failing pig myocytes. Circ Res 92: 897-903, 2003
36. Reiken S, Gaburjakova M, Guatimosim S, Gomez AM, D'Armiento J, Burkhoff D, Wang J, Vassort G, Lederer WJ, Marks AR: Protein kinase A phosphorylation of the cardiac calcium release channel ryanodine receptor in normal and failing hearts. Role of phosphatases and responses to isoproterenol. J Biol Chem 278: 444-453, 2003
37. Horiuchi M, Hayashida W, Kambe T, Yamada T, Dzau VJ: Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem 272: 19022-19026, 1997
38. 2+ -calmodulin-dependent protein kinase activity and expression in LV myocardium of dogs with heart failure Am J Physiol Heart Circ Physiol 284: H876-H883, 2003
39. El-Armouche A, Rau T, Zolk O, Ditz D, Pamminger T, Zimmermann WH, Jackel E, Harding SE, Boknik P, Neumann J, Eschenhagen T: Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes. FASEB J 17: 437-439, 2003
40. Williams JP, Jo H, Hunnicut RE, Brautigan DL, McDonald JM: Tyrosine phosphorylation of phosphatase inhibitor 2. J Cell Biochem 57: 415-422, 1995
41. Takeishi Y, Huang Q, Abe JI, Che W, Lee JW, Kawakatsu H, Hoit BD, Berk BC, Walsh RA: Activation of mitogen-activated protein kinases and p90 ribosomal S6 kinase in failing human hearts with dilated cardiomyopathy. Cardiovasc Res 53: 131-137, 2002